Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6RQXB)

• Drug Name: CNTO-6785 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM6RQXB

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-17 (IL17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brodalumab	DMASDQ6	Plaque psoriasis	EA90.0	Approved	[4]
Bimekizumab	DMR9TF1	Plaque psoriasis	EA90.0	Approved	[5]
Ixekizumab	DMXW92T	Plaque psoriasis	EA90.0	Approved	[6]
ABT-122	DM23UQ9	Psoriatic arthritis	FA21	Phase 2	[7]
CJM112	DMTSVJM	Acne vulgaris	ED80	Phase 2	[8]
COVA322	DM824EG	Psoriasis vulgaris	EA90	Phase 1/2a	[9]
SHR-1314	DMADNY3	Plaque psoriasis	EA90.0	Phase 1/2	[5]
ABBV-257	DMCZI8L	Rheumatoid arthritis	FA20	Phase 1	[2]
ALX-0761	DMJ8ACF	Psoriasis vulgaris	EA90	Phase 1	[9]
SCH-900117	DM7A6R5	Rheumatoid arthritis	FA20	Phase 1	[10]

Drug(s) Targeting Interleukin 17 receptor (IL17R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brodalumab	DMASDQ6	Plaque psoriasis	EA90.0	Approved	[11]
CAT-2200	DMWHP52	Rheumatoid arthritis	FA20	Investigative	[12]
ANA-04	DMIY134	Autoimmune diabetes	5A10	Investigative	[12]
NI-1401	DMG9OBA	Autoimmune diabetes	5A10	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 17 receptor (IL17R)	TT69OHW	I17RA_HUMAN; I17RB_HUMAN; I17RC_HUMAN; I17RD_HUMAN; I17RE_HUMAN	Not Available	[2]
Interleukin-17 (IL17)	TTG0MT6	IL17_HUMAN	Not Available	[3]

References

• [1] ClinicalTrials.gov (NCT01909427) An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
• [7] DOI: 10.1136/annrheumdis-2015-eular.4042
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [10] Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76.
• [11] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2294).